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Abstract
Microvolt T-wave alternans (MTWA) is a promising non-invasive method of evaluating
repolarization abnormalities. Its presence is strongly related to the occurrence of malignant
ventricular tachyarrhythmias and is therefore regarded as a risk marker for sudden cardiac
death. Most recent studies have described the usefulness of MTWA in selecting patients who
may benefit from a cardioverter-defibrillator.
This study presents two cases of patients suffering from ischemic cardiomyopathy, who under-
went an MTWA test. Episodes of ventricular tachycardia occurred immediately after the end of
the tests, with abnormal results. (Cardiol J 2009; 16, 4: 365–367)
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Introduction
Microvolt T-wave alternans (MTWA) is a mi-
crovolt change in T-wave amplitude in every other
beat. It is strongly correlated with the susceptibi-
lity to malignant ventricular tachyarrhythmias [1].
In recent years its relevance in predicting sudden
cardiac death (SCD) and life-threatening arrhyth-
mias has been documented in high risk patient
groups [2, 3]. These observations are based on long-
term follow-up studies. Our paper describes two
cases of cardioverter-defibrillator (ICD) recipients
who experienced ventricular tachycardias.
MTWA assessment
MTWA tests were performed using equipment
manufactured by System Cambridge Heart Inc.,
Bedford, MA, USA, and were carried out during
a treadmill exercise. The test was defined as positive
when the sustained alternans voltage was > 1.9 mV
(with an alternans ratio > 3.0) for at least one
minute with an onset heart rate < 110 bpm in two
consecutive precordial leads or any orthogonal lead
during exercise. The test was defined as negative
when the positive criteria were not met at heart rate
> 105 bpm and the data was free from any defects.
If neither positive nor negative criteria were met,
the test was defined as indeterminate [4]. Positive
and indeterminate results were grouped together
and constituted abnormal MTWA results [4]. Drug
treatment involving beta-adrenolytics was not dis-
continued before the MTWA test.
Case 1
A 54 year-old woman who had experienced
anterior myocardial infarction 29 years previously
which had been treated conservatively, was hospi-
talized due to clinical and electrocardiographical
symptoms suggesting unstable coronary artery dis-
ease with accompanying sustained VT (sVT). The
ejection fraction in echocardiography decreased to
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40%, the apex was akinetic and moderate mitral
regurgitation was diagnosed.
Coronarography did not show significant sten-
osis in coronary arteries. The patient thus qualified
for ICD. Before implantation, an MTWA test was
performed and the result was positive. Approxi-
mately two minutes after the exercise, during the
recovery phase, monomorphic sVT occurred with
a rate of 180 bpm, which was terminated by intra-
venous amiodarone. sVT following positive MTWA
is presented in Figure 1.
Case 2
A 62 year-old woman with stable coronary
artery disease and prior inferior wall myocardial
infarction qualified for ICD implantation due to re-
current sVT. Ischemia had been excluded as the
cause of the arrhythmia. Ejection fraction in
echocardiography decreased to 40%. Following
ICD placement, an MTWA test was performed to
assess the risk of future malignant arrhythmias.
The test was indeterminate due to numerous ven-
tricular ectopic beats. Ventricular tachycardia
occurred during recovery but was successfully
terminated by ICD antitachycardia pacing. Indeter-
minate MTWA and the arrhythmic event in the
recovery phase of the test recorded in the ICD
memory are shown in Figure 2.
Figure 1. Positive microvolt T-wave alternans in a patient
with ischemic cardiomyopathy (A) and ventricular tachy-
cardia recorded during recovery after the test (B).
Figure 2. Indeterminate microvolt T-wave alternans in an
ischemic implantable cardioverter-defibrillator (ICD) reci-
pient (A) and ventricular tachycardia, documented in ele-
ctrogram, successfully terminated by antiarrhythmic
tachycardia pacing (ATP) delivered by ICD during the re-
covery phase of the microvolt T-wave alternans  test (B).
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Discussion
These two cases present clear clinical evidence
of the dependence between abnormal MTWA and
the propensity to arrhythmic events in patients with
implanted ICDs in secondary SCD prevention. Over
the last decade, several studies have documented
the role of MTWA in SCD risk stratification. Meta-
analysis of 19 MTWA studies with a mean follow-
up period of 21 months performed by Gehi et al. [5]
revealed a 97.2% negative predictive value of
MTWA, 19.3% positive predictive value and an
unadjusted relative risk of 3.77 in the prediction of
arrhythmic events. The Alternans Before Cardio-
verter Defibrillator trial, the first to have used
MTWA to guide ICD therapy, showed that non-in-
vasive MTWA-guided risk stratification predicts
arrhythmic events as reliably as invasive electro-
physiological study [6]. Moreover, the event rate
in patients with two negative tests was very low
(2%) [6]. The usefulness of MTWA in stratification
of patients for ICD implantation was acknowledged
in the new SCD ACC/AHA/ESC guidelines, with
class IIa level of evidence A [7]. The most recent
study, by Chow and involving patients with ischemic
cardiomyopathy and ICD implanted for primary
SCD prevention, revealed at 27-month follow-up
a greater mortality rate in the group with abnormal
MTWA [8]. Most studies of risk stratification con-
sider as abnormal MTWA which combines positive
and indeterminate results [2, 8]. It is particularly
justified when frequent ventricular ectopic beats
occur during the test [4, 8]. Such a situation oc-
curred in our Case 2, where the indeterminate
MTWA result was due to many ventricular prema-
ture complexes.
Our cases, with immediate arrhythmic events
following abnormal MTWA, indicate that those who
will benefit from ICD implementation are ICD re-
cipients characterized by abnormal MTWA.
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